IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present scientific posters at the following conferences in November 2019. The Huntington Study Group 2019 Annual Meeting 7 – 9 November 2019, Sacramento, California, USA IXICO will present a poster entitled “A Fully […]
-Neuraxpharm establishes Swiss footprint with acquisition of leading cannabidiol company -S.T.U. GmbH is the owner of market leading brand Hemplix™ October 29, 2019 Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces today the acquisition of S.T.U. GmbH (Swiss Trade Union or S.T.U.), a leading Switzerland-based developer […]
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces three new biopharma contracts and the appointment of Lammert Albers as Chief Business Officer effective immediately. The new contracts are: · A start up agreement with a new client for a new multi-study programme in Progressive Supranuclear Palsy (PSP), with […]
Amsterdam, The Netherlands, 22 October 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts in the field of oncology and cell therapy. The SAB will provide invaluable scientific expertise and […]
Results to Inform Development Plan and Dose Selection for Phase 3 LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as […]
